Patents by Inventor Jayaraman Chandrasekhar
Jayaraman Chandrasekhar has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).
-
Publication number: 20210115037Abstract: The present disclosure relates generally to certain 6-azabenzimidazole compounds, pharmaceutical compositions comprising said compounds, and methods of making and using said compounds and pharmaceutical compositions. The compounds and compositions disclosed herein may be used for the treatment or prevention of diseases, disorders, or infections modifiable by hematopoietic progenitor kinase 1 (HPK1) inhibitors, such as HBV, HIV, cancer, and/or a hyper-proliferative disease.Type: ApplicationFiled: October 30, 2019Publication date: April 22, 2021Inventors: Gayatri Balan, Mark J. Bartlett, Jayaraman Chandrasekhar, Julian A. Codelli, John H. Conway, Jennifer L. Cosman, Rao V. Kalla, Zachary A. Kasun, Musong Kim, Seung H. Lee, Jennifer R. Lo, Jennifer A. Loyer-Drew, Scott A. Mitchell, Thao D. Perry, Gary B. Phillips, Patrick J. Salvo, Sundaramoorthi Swaminathan, Joshua J. Van Veldhuizen, Suet C. Yeung, Jeff Zablocki
-
Publication number: 20210053967Abstract: The present disclosure provides a compound of Formula (I): or a pharmaceutically acceptable salt thereof as described herein. The present disclosure also provides pharmaceutical compositions comprising a compound of Formula (I), processes for preparing compounds of Formula (I), therapeutic methods for treating inflammatory disease.Type: ApplicationFiled: August 12, 2020Publication date: February 25, 2021Inventors: Peter A. Blomgren, Taryn L. Campbell, Jayaraman Chandrasekhar, Christopher T. Clark, Kevin S. Currie, Jeffrey E. Kropf, Yasamin Moazami, Nicole A. Nava, Leena Patel, Jason K. Perry, Natalie Seeger, Kirk L. Stevens, Zhongdong Zhao
-
Publication number: 20200392153Abstract: The present disclosure relates generally to certain ene-oxindole compounds, pharmaceutical compositions comprising thereof. Also disclosed are methods of making and using said compounds and pharmaceutical compositions. The compounds and compositions disclosed herein may be used for the treatment or prevention of diseases, disorders, or infections modifiable by hematopoietic progenitor kinase 1 (HPK1) inhibitors, such as HBV, HIV, cancer, and/or a hyper-proliferative disease.Type: ApplicationFiled: May 21, 2020Publication date: December 17, 2020Inventors: Evangelos Aktoudianakis, Jayaraman Chandrasekhar, Julian A. Codelli, John H. Conway, Kristyna M. Elbel, Rao V. Kalla, Samuel E. Metobo, Scott A. Mitchell, Thao D. Perry, Scott P. Simonovich, Christopher A. Ziebenhaus
-
Publication number: 20200171020Abstract: The present disclosure relates generally to certain 6-azabenzimidazole compounds, pharmaceutical compositions comprising said compounds, and methods of making and using said compounds and pharmaceutical compositions. The compounds and compositions disclosed herein may be used for the treatment or prevention of diseases, disorders, or infections modifiable by hematopoietic progenitor kinase 1 (HPK1) inhibitors, such as HBV, HIV, cancer, and/or a hyper-proliferative disease.Type: ApplicationFiled: October 30, 2019Publication date: June 4, 2020Inventors: Gayatri Balan, Mark J. Bartlett, Jayaraman Chandrasekhar, Julian A. Codelli, John H. Conway, Jennifer L. Cosman, Rao V. Kalla, Musong Kim, Seung H. Lee, Jennifer R. Lo, Jennifer A. Loyer-Drew, Scott A. Mitchell, Thao D. Perry, Gary B. Phillips, Patrick J. Salvo, Joshua J. Van Veldhuizen, Suet C. Yeung, Jeff Zablocki
-
Publication number: 20200163953Abstract: The present disclosure provides a compound of Formula (I): or a pharmaceutically acceptable salt thereof as described herein. The present disclosure also provides pharmaceutical compositions comprising a compound of Formula (I), processes for preparing compounds of Formula (I), and therapeutic methods for treating inflammatory disease.Type: ApplicationFiled: October 29, 2019Publication date: May 28, 2020Inventors: Peter A. Blomgren, Taryn Campbell, Jayaraman Chandrasekhar, Christopher T. Clark, Julian A. Codelli, Kevin S. Currie, Jeffrey E. Kropf, Yasamin Moazami, Nicole Nava, Leena Patel, Stephane Perreault, Jason K. Perry, Kassandra F. Sedillo, Natalie Seeger, Kirk L. Stevens, Jennifer Anne Treiberg, Suet C. Yeung, Zhongdong Zhao
-
Publication number: 20200165248Abstract: The present disclosure provides a compound of Formula (I): or a pharmaceutically acceptable salt thereof as described herein. The present disclosure also provides pharmaceutical compositions comprising a compound of Formula (I), processes for preparing compounds of Formula (I), and therapeutic methods for treating inflammatory disease.Type: ApplicationFiled: October 29, 2019Publication date: May 28, 2020Inventors: Peter A. Blomgren, Taryn Campbell, Jayaraman Chandrasekhar, Christopher T. Clark, Julian A. Codelli, Kevin S. Currie, Jeffrey E. Kropf, Yasamin Moazami, Nicole Nava, Leena Patel, Stephane Perreault, Jason K. Perry, Kassandra F. Sedillo, Natalie Seeger, Kirk L. Stevens, Jennifer Anne Treiberg, Suet C. Yeung, Zhongdong Zhao
-
Publication number: 20200155538Abstract: The present disclosure provides a compound of Formula (I): or a pharmaceutically acceptable salt thereof as described herein. The present disclosure also provides pharmaceutical compositions comprising a compound of Formula (I), processes for preparing compounds of Formula (I), and therapeutic methods for treating inflammatory disease.Type: ApplicationFiled: October 29, 2019Publication date: May 21, 2020Inventors: Peter A. Blomgren, Taryn Campbell, Jayaraman Chandrasekhar, Christopher T. Clark, Julian A. Codelli, Kevin S. Currie, Jeffrey E. Kropf, Yasamin Moazami, Nicole Nava, Leena Patel, Stephane Perreault, Jason K. Perry, Kassandra F. Sedillo, Natalie Seeger, Kirk L. Stevens, Jennifer Anne Treiberg, Suet C. Yeung, Zhongdong Zhao
-
Publication number: 20200155563Abstract: The present disclosure provides a compound of Formula (I): or a pharmaceutically acceptable salt thereof as described herein. The present disclosure also provides pharmaceutical compositions comprising a compound of Formula (I), processes for preparing compounds of Formula (I), and therapeutic methods for treating inflammatory disease.Type: ApplicationFiled: October 29, 2019Publication date: May 21, 2020Inventors: Peter A. Blomgren, Taryn Campbell, Jayaraman Chandrasekhar, Christopher T. Clark, Julian A. Codelli, Kevin S. Currie, Jeffrey E. Kropf, Yasamin Moazami, Nicole Nava, Leena Patel, Stephane Perreault, Jason K. Perry, Kassandra F. Sedillo, Natalie Seeger, Kirk L. Stevens, Jennifer Anne Treiberg, Suet C. Yeung, Zhongdong Zhao
-
Patent number: 10479770Abstract: The present application provides the compounds of formula I or pharmaceutically acceptable salts, isomers, tautomer, or a mixture thereof, wherein t, R1, R2, R3, R4, and R6 are as described herein.Type: GrantFiled: September 21, 2017Date of Patent: November 19, 2019Assignee: Gilead Sciences, Inc.Inventors: Jayaraman Chandrasekhar, Devan Naduthambi, Leena Patel, Stephane Perreault, Gary Phillips, Kassandra F. Sedillo, Nicholas Alexander Till, Jennifer Anne Treiberg, William J. Watkins, Julian A. Codelli, Joshua J. Van Veldhuizen
-
Patent number: 10227350Abstract: The present application provides the compounds of formula I or pharmaceutically acceptable salts, isomers, tautomer, or a mixture thereof, wherein s, t, n, R1, R2, R3, R4, R5, and R6 are as described herein.Type: GrantFiled: September 21, 2017Date of Patent: March 12, 2019Assignee: Gilead Sciences, Inc.Inventors: Jayaraman Chandrasekhar, Leena Patel, Stephane Perreault, Gary Phillips, Nicholas Alexander Till, Jennifer Anne Treiberg
-
Patent number: 10214519Abstract: The present application provides the compounds of formula I or IA or pharmaceutically acceptable salts, isomers, tautomer, or a mixture thereof, wherein s, t, m, n, R1, R2, R3, R4, R5, R6 and R7 are as described herein.Type: GrantFiled: September 21, 2017Date of Patent: February 26, 2019Assignee: Gilead Sciences, Inc.Inventors: Jayaraman Chandrasekhar, Julian Andrew Codelli, Devan Naduthambi, Leena Patel, Stephane Perreault, Gary Phillips, Kassandra F. Sedillo, Jennifer Anne Treiberg, Joshua Van Veldhuizen, William J. Watkins
-
Patent number: 10005774Abstract: The present disclosure relates to compounds that are Syk inhibitors and to their use in the treatment of various disease states, including cancer and inflammatory conditions. In particular embodiments, the structure of the compounds is given by Formula I: wherein X1, X2, X3, R2, R3, R4, R5, and Y are as described herein. The present disclosure further provides pharmaceutical compositions that include a compound of Formula I, or pharmaceutically acceptable salts thereof, and methods of using these compounds and compositions to treat conditions mediated by Syk.Type: GrantFiled: May 9, 2016Date of Patent: June 26, 2018Assignee: Gilead Sciences, Inc.Inventors: Peter A. Blomgren, Jayaraman Chandrasekhar, Kevin S. Currie, Zhimin Du, Julie Farand, Juan A. Guerrero, Ashley A. Katana, Darryl Kato, Jeffrey E. Kropf, Scott E. Lazerwith, Seung H. Lee, Jiayao Li, John O. Link, Jennifer R. Lo, Nicholas Mai, Scott A. Mitchell, Gregory Notte, Hyung-jung Pyun, Michael Sangi, Aaron C. Schmitt, Adam J. Schrier, Kirk L. Stevens, Chandrasekar Venkataramani, William J. Watkins, Jin-Ming Xiong, Jianjun Xu, Zheng-Yu Yang, Jeff Zablocki, Zhongdong Zhao, Sheila Zipfel
-
Publication number: 20180086768Abstract: The present application provides the compounds of formula I or pharmaceutically acceptable salts, isomers, tautomer, or a mixture thereof, wherein s, t, n, R1, R2, R3, R4, R5, and R6 are as described herein.Type: ApplicationFiled: September 21, 2017Publication date: March 29, 2018Inventors: Jayaraman Chandrasekhar, Leena Patel, Stephane Perreault, Gary Phillips, Nicholas Alexander Till, Jennifer Anne Treiberg
-
Publication number: 20180086719Abstract: The present application provides the compounds of formula I or pharmaceutically acceptable salts, isomers, tautomer, or a mixture thereof, wherein t, R1, R2, R3, R4, and R6 are as described herein.Type: ApplicationFiled: September 21, 2017Publication date: March 29, 2018Inventors: Jayaraman Chandrasekhar, Devan Naduthambi, Leena Patel, Stephane Perreault, Gary Phillips, Kassandra F. Sedillo, Nicholas Alexander Till, Jennifer Anne Treiberg, William J. Watkins
-
Publication number: 20180086747Abstract: The present application provides the compounds of formula I or IA or pharmaceutically acceptable salts, isomers, tautomer, or a mixture thereof, wherein s, t, m, n, R1, R2, R3, R4, R5, R6 and R7 are as described herein.Type: ApplicationFiled: September 21, 2017Publication date: March 29, 2018Inventors: Jayaraman Chandrasekhar, Julian Andrew Codelli, Devan Naduthambi, Leena Patel, Stephane Perreault, Gary Phillips, Kassandra F. Sedillo, Jennifer Anne Treiberg, Joshua Van Veldhuizen, William J. Watkins
-
Publication number: 20160368918Abstract: The present disclosure relates to compounds that are Syk inhibitors and to their use in the treatment of various disease states, including cancer and inflammatory conditions. In particular embodiments, the structure of the compounds is given by Formula I: wherein X1, X2, X3, R2, R3, R4, R5, and Y are as described herein. The present disclosure further provides pharmaceutical compositions that include a compound of Formula I, or pharmaceutically acceptable salts thereof, and methods of using these compounds and compositions to treat conditions mediated by Syk.Type: ApplicationFiled: May 9, 2016Publication date: December 22, 2016Inventors: Peter Blomgren, Jayaraman Chandrasekhar, Kevin S. Currie, Zhimin Du, Julie Farand, Juan A. Guerrero, Ashley A. Katana, Darryl Kato, Jeffrey Kropf, Scott E. Lazerwith, Seung H. Lee, Jiayao Li, John O. Link, Jennifer R. Lo, Nicholas Mai, Scott A. Mitchell, Gregory Notte, Hyung-jung Pyun, Michael Sangi, Aaron C. Schmitt, Adam J. Schrier, Kirk L. Stevens, Chandrasekar Venkataramani, William J. Watkins, Jin Ming Xiong, Jianjun Xu, Zheng-Yu Yang, Jeff Zablocki, Zhongdong Zhao, Sheila Zipfel
-
Patent number: 9376441Abstract: The present disclosure relates to compounds that are Syk inhibitors and to their use in the treatment of various disease states, including cancer and inflammatory conditions. In particular embodiments, the structure of the compounds is given by Formula I: wherein X1, X2, X3, R2, R3, R4, R5, and Y are as described herein. The present disclosure further provides pharmaceutical compositions that include a compound of Formula I, or pharmaceutically acceptable salts thereof, and methods of using these compounds and compositions to treat conditions mediated by Syk.Type: GrantFiled: July 31, 2014Date of Patent: June 28, 2016Assignee: Gilead Sciences, Inc.Inventors: Kevin S. Currie, Zhimin Du, Julie Farand, Juan A. Guerrero, Ashley A. Katana, Darryl Kato, Scott E. Lazerwith, Jiayao Li, John O. Link, Nicholas Mai, Gregory Notte, Hyung-jung Pyun, Michael Sangi, Aaron C. Schmitt, Adam J. Schrier, Kirk L. Stevens, Chandrasekar Venkataramani, William J. Watkins, Zheng-Yu Yang, Jeff Zablocki, Sheila Zipfel, Jennifer R. Lo, Seung H. Lee, Zhongdong Zhao, Jeffrey Kropf, Jianjun Xu, Peter Blomgren, Scott A. Mitchell, JinMing Xiong, Jayaraman Chandrasekhar
-
Publication number: 20130338142Abstract: Certain imidazopyrazines and pharmaceutical compositions thereof are provided herein. Methods of treating patients suffering from certain diseases and disorders responsive to the inhibition of Syk activity, which comprises administering to such patients an amount of an imidazopyrazine compound effective to reduce signs or symptoms of the disease or disorder are provided.Type: ApplicationFiled: June 14, 2013Publication date: December 19, 2013Inventors: Peter A. BLOMGREN, Kevin S. CURRIE, Randall HALCOMB, Jeffrey E. KROPF, Seung H. LEE, Jiayao LI, Jennifer R. LO, Scott A. MITCHELL, Aaron SCHMITT, Qiaoyin WU, Jin-Min XIONG, Jianjun XU, Zhongdong ZHAO, Jayaraman CHANDRASEKHAR, Eric LANSDON
-
Publication number: 20130184313Abstract: The invention relates to pyridinyl nicotinic acetylcholine receptor ligands, compositions comprising an effective amount of a pyridinyl nicotinic acetylcholine receptor ligand and methods to treat or prevent a condition, such as depression and nicotine dependence, comprising administering to an animal in need thereof an effective amount of a pyridinyl nicotinic acetylcholine receptor ligand.Type: ApplicationFiled: March 7, 2013Publication date: July 18, 2013Applicants: The Board of Trustees of the University of Illinois, PsychoGenics, Inc.Inventors: Jayaraman Chandrasekhar, Alan P. Kozikowski, Jianhua Liu, Werner Tueckmantel, Joel R. Walker, Po-wai Yuen
-
Patent number: 8445684Abstract: The invention relates to pyridinyl nicotinic acetylcholine receptor ligands, compositions comprising an effective amount of a pyridinyl nicotinic acetylcholine receptor ligand and methods to treat or prevent a condition, such as depression and nicotine dependence, comprising administering to an animal in need thereof an effective amount of a pyridinyl nicotinic acetylcholine receptor ligand.Type: GrantFiled: October 13, 2009Date of Patent: May 21, 2013Assignees: PsycoGenics Inc., The Board of Trustee of the University of ILInventors: Jayaraman Chandrasekhar, Alan P. Kozikowski, Jianhua Liu, Werner Tueckmantel, Joel R. Walker, Po-wai Yuen